Track topics on Twitter Track topics that are important to you
OVERLAND PARK, Kan., June 1, 2015 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that the company will hold its first Investor Day event for the institutional investment and research analyst community on Thursday, June 18th, 2015 in New York City. Registration begins at 8 am and the formal presentation and webcast will began at 8:30 am Eastern time.
Management will present results from the Pivotal Efficacy Clinical Study of Zydax®, Parnell's disease-modifying osteoarthritis therapy for dogs and horses, as well as global commercialization plans for Zydax and Glyde®, Parnell's nutraceutical product for osteoarthritis management. The program will feature in-depth presentations by Parnell's executive team on development progress in Parnell's new product pipeline, and noted industry experts will provide insights into new and emerging markets in the animal healthcare industry.
The event will be hosted by Chief Executive Officer Robert Joseph and Chief Scientific Officer Edward Robb, DVM, MS, DAC, VN, as well as featured expert speakers:
Qualified institutional investors and research analysts may register to attend the Parnell 2015 Investor Day by contacting Karen Bergman or Susan Pietropaolo, BCC Partners at email@example.com or firstname.lastname@example.org.
Parnell invites the public to listen to the presentations via a live webcast that will be accessible under the Investor Relations section of the company's website, http://investors.parnell.com/events.cfm. Parnell will maintain an archived replay of the webcast on its website for 30 days after the conference.
Parnell (Nasdaq:PARN) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. Parnell currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical products with proprietary software platforms - iKAM and mySYNCH. These innovative technology solutions are designed to enhance the quality of life and/or performance of animals, while driving customers' operational efficiency and profitability. Parnell distinguishes itself in the industry by providing value-added solutions that position the Company as a true partner to their customers.
For more information on the company and its products, please visit www.parnell.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of the U.S. Private Securities Reform Act of 1995. Words such as "may," "anticipate," "estimate," "expects," "projects," "intends," "plans," "develops," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. Forward-looking statements represent management's present judgment regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding Parnell's research and development activities, its ability to conduct clinical trials of product candidates and the results of such trials, as well as risks and uncertainties relating to litigation, government regulation, economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on third parties, and other factors, including those described in Parnell's Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on September 15, 2014, along with its other reports filed with the SEC. In light of these assumptions, risks, and uncertainties, the results and events discussed in any forward-looking statements contained in this press release might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Parnell is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise.
CONTACT: For more information, contact: Parnell Pharmaceuticals Holdings Robert Joseph, 913-274-2100 Robert.email@example.com BCC Partners Karen Bergman, 650-575-1509 firstname.lastname@example.org Susan Pietropaolo, 845-638-6290 email@example.comNEXT ARTICLE
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
Arthritis is by definition the inflammation of one or more joints, characterized by swelling, pain, warmth, redness and diminished range of joint movement (Oxford Medical Dictionary). There are many different types; Noninflammatory; Osteoarthritis, N...